Page last updated: 2024-12-05

morpholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Morpholine is a heterocyclic organic compound with the formula (CH2CH2)2NH. It is a colorless liquid with an ammonia-like odor. Morpholine is used as a solvent, a corrosion inhibitor, and a precursor to other chemicals. Morpholine is synthesized by reacting diethanolamine with ammonia. Morpholine is used in the production of pesticides, pharmaceuticals, and other chemicals. Morpholine is studied because of its potential applications in a variety of industries. It is also studied because of its potential environmental impact.'

Cross-References

ID SourceID
PubMed CID8083
CHEMBL ID276518
CHEBI ID34856
MeSH IDM0113608

Synonyms (100)

Synonym
BIDD:ER0297
CHEBI:34856 ,
NCIMECH_000154
110-91-8
diethylenimide oxide
tetrahydro-1,4-isoxazine
p-isoxazine, tetrahydro-
tetrahydro-2h-1,4-oxazine
basf 238
nsc9376
wln: t6m dotj
diethylene imidoxide
nsc-9376
morpholine ,
4h-1, tetrahydro-
tetrahydro-1,4-oxazine
1-oxa-4-azacyclohexane
diethyleneimide oxide
diethylene oximide
tetrahydro-p-oxazine
morpholine, pract
morpholine,reag
OPREA1_317540
inchi=1/c4h9no/c1-3-6-4-2-5-1/h5h,1-4h
einecs 203-815-1
epa pesticide chemical code 054701
ai3-01231
brn 0102549
nsc 9376
drewamine
caswell no. 584
c4h9no
ccris 2482
un2054
morpholine [un2054] [flammable liquid]
4h-1,4-oxazine, tetrahydro-
2h-1,4-oxazine, tetrahydro-
hsdb 102
morpholine, purified by redistillation, >=99.5%
morpholine, acs reagent, >=99.0%
morpholine, reagentplus(r), >=99%
NCIOPEN2_007748
tetrahydro-4h-1-4-oxazine
AKOS000118829
CHEMBL276518
M0465
NCGC00249227-01
morpholin
dtxcid305688
cas-110-91-8
tox21_303240
NCGC00256942-01
dtxsid2025688 ,
NCGC00259999-01
tox21_202450
1,4-oxazinane
8b2zck305o ,
4-27-00-00015 (beilstein handbook reference)
morpholine [un2054] [flammable liquid]
ec 203-815-1
unii-8b2zck305o
morpholine [mi]
morpholine [fcc]
morpholine [hsdb]
morpholine [inci]
morpholine [iarc]
138048-80-3
un 2054
na 2054
morphline
morpho line
morpholine-
STR00194
6lr ,
mfcd00005972
J-522715
F2190-0339
morpholine, analytical standard
tetrahydro-p-isoxazine
scavengepore(tm) phenethyl morpholine, macroporous, 40-70 mesh, extent of labeling: 0.7-1.5 mmol/g loading
stratospheres(tm) pl-mph resin, 50-100 mesh, extent of labeling: 3.0-4.0 mmol/g loading, 1 % cross-linked
morpholine, p.a., acs reagent, 99.0%
morpholine; molsidomine imp. e (ep); molsidomine impurity e
morpholine on rasta resin
tetrahydro-4h-1,4-oxazine
tetryhydro-2h-1,4-oxazine
tetrahydro-1, 4-isoxazine
morpholine purified by distillation from glass
BCP24054
Q410243
FT-0628993
DB13669
AMY22834
EN300-18064
STL182843
morpholine (basf)
dieythylene oximide
morpholine (iarc)
usepa/opp pesticide code: 054701
tetrahydro-2h-1, 4-oxazine

Research Excerpts

Overview

Morpholine is a heterocycle featured in numerous approved and experimental drugs as well as bioactive molecules. It is a versatile moiety, a privileged pharmacophore and an outstanding heterocyclic motif with wide ranges of pharmacological activities.

ExcerptReferenceRelevance
"Morpholine is a heterocycle featured in numerous approved and experimental drugs as well as bioactive molecules. "( Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules.
Kourounakis, AP; Tzara, A; Xanthopoulos, D, 2020
)
3.44
"Morpholine is a versatile moiety, a privileged pharmacophore and an outstanding heterocyclic motif with wide ranges of pharmacological activities due to different mechanisms of action. "( Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR).
Kumari, A; Singh, RK, 2020
)
3.44
"Morpholine is a frequently used heterocycle in medicinal chemistry and a privileged structural component of bioactive molecules. "( Morpholine As a Scaffold in Medicinal Chemistry: An Update on Synthetic Strategies.
Kourounakis, AP; Tzara, A; Xanthopoulos, D, 2020
)
3.44
"Morpholine is a common chemical used as emulsifier in the preparation of wax coatings for some fruit to help them remain fresh and protect against insects and fungal contamination. "( Concentration of morpholine residues in major fruits and juices and its dietary exposure in China.
Cao, P; Chen, DW; Liang, J; Liu, SJ; Wei, J; Wen, S; Wu, PG; Wu, XM; Xu, HB; Zhao, YF, 2019
)
2.3

Bioavailability

ExcerptReferenceRelevance
" Administration of the reactants together with food decreased the NMOR level in blood 155-fold relative to controls (no food), suggesting that food decreased the absorption rate over a 30-min period."( Effects of phenol and 2,6-dimethoxyphenol (syringol) on in vivo formation of N-nitrosomorpholine in rats.
Issenberg, P; Virk, MS, 1986
)
0.49
" KMS99220 exhibited a favorable pharmacokinetic profile with excellent bioavailability and metabolic stability, did not interfere with activities of the cytochrome p450 isotypes, and showed no apparent in vivo toxicity when administered up to 2000 mg/kg."( Activation of the Nrf2 signaling pathway and neuroprotection of nigral dopaminergic neurons by a novel synthetic compound KMS99220.
Choi, JW; Han, SH; Heo, JY; Hwang, O; Kim, DJ; Kim, J; Kim, JH; Kim, SJ; Lee, JA; Park, KD; Shin, N; Son, HJ, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" This process is not influenced by simultaneous dosage with large amounts of NaNO3."( Endogenous incorporation of nitric oxide from L-arginine into N-nitrosomorpholine stimulated by Escherichia coli lipopolysaccharide in the rat.
Leaf, CD; Tannenbaum, SR; Wishnok, JS, 1991
)
0.51
" The daily levels of NMOR formation were highly variable, but the mean level was consistent with the tumorigenicity data in that dose-response study."( A sensitive new method for the detection of N-nitrosomorpholine formation in vivo.
Hecht, SS; Morrison, JB, 1984
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
NMR chemical shift reference compoundAny compound that produces a peak used to reference an NMR spectrum during data pre-processing.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
saturated organic heteromonocyclic parent
morpholinesAny compound containing morpholine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency34.37620.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency65.72080.000714.592883.7951AID1259369; AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency8.56700.000657.913322,387.1992AID1259377; AID1259394
progesterone receptorHomo sapiens (human)Potency65.13050.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency54.69580.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency76.95880.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency13.80060.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.36930.000229.305416,493.5996AID743075
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency48.55770.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID350219Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID103502Effective concentration of compound necessary to kill 50% of infective larvae of Molinema dessetae after 7 days was determined in vitro1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
New antifilarial agents. 1. Epoxy sulfonamides and ethynesulfonamides.
AID103505Effective in vitro concentration necessary to kill 90% of infective larvae of Molinema dessetae after 7 days1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
New antifilarial agents. 1. Epoxy sulfonamides and ethynesulfonamides.
AID701844Dissociation constant, pKa of the compound2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Mitigating heterocycle metabolism in drug discovery.
AID1306441Inhibition of recombinant human CYP1A1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1306442Inhibition of recombinant human CYP1B1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH at 100 uM measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID1306440Inhibition of recombinant human CYP1A1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH at 100 uM measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID350220Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID350218Octanol-water partition coefficient, log PC of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID350216Dissociation constant, pKa of the compound2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
AID1672276Acid dissociation constant, pKa of the compound2019ACS medicinal chemistry letters, Mar-14, Volume: 10, Issue:3
Second Generation Inhibitors of HIV-1 Maturation.
AID1306443Inhibition of recombinant human CYP1B1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (311)

TimeframeStudies, This Drug (%)All Drugs %
pre-199060 (19.29)18.7374
1990's31 (9.97)18.2507
2000's76 (24.44)29.6817
2010's118 (37.94)24.3611
2020's26 (8.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.08 (24.57)
Research Supply Index5.80 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index111.02 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (2.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other321 (97.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]